Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis
Introduction: L-carnosine has been found to have multimodal activity. Aim: The aim of this review was to find out the efficacy of L-carnosine in patients with age-related diseases. Methods: Clinical studies evaluated the effect of L-carnosine on cancer, cardiovascular disease, diabetes, and neurodeg...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-01-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/28/1/10.31083/j.fbl2801018 |
| _version_ | 1797937667220963328 |
|---|---|
| author | Kaoshik Sureshkumar Mahesh Durairaj Kaviya Srinivasan Khang Wen Goh Krishna Undela Vijayakumar Thangavel Mahalingam Chrismawan Ardianto Long Chiau Ming Rajanandh Muhasaparur Ganesan |
| author_facet | Kaoshik Sureshkumar Mahesh Durairaj Kaviya Srinivasan Khang Wen Goh Krishna Undela Vijayakumar Thangavel Mahalingam Chrismawan Ardianto Long Chiau Ming Rajanandh Muhasaparur Ganesan |
| author_sort | Kaoshik Sureshkumar |
| collection | DOAJ |
| description | Introduction: L-carnosine has been found to have multimodal activity. Aim: The aim of this review was to find out the efficacy of L-carnosine in patients with age-related diseases. Methods: Clinical studies evaluated the effect of L-carnosine on cancer, cardiovascular disease, diabetes, and neurodegenerative disorders were searched in electronic bibliographic databases. The protocol has been registered with PROSPERO (CRD42022314033). The revised Cochrane risk of bias tool for randomized trials was used to assess all of the reports for risk of bias. RevMan 5.4 was used to conduct the meta-analysis. Results: Following the screening process, 14 papers were selected for systematic review, with 9 of them being qualified for meta-analysis. Many of the included studies showed that L-carnosine has potential therapeutic activity in age related diseases. Results from the meta-analysis showed that in diabetes mellitus, HbA1c [mean difference (MD) 95% CI = –1.25 (–2.49, –0.022); p = 0.05; p = 0.001; I2 = 85%] and fasting blood sugar (FBS) [MD 95% CI = –12.44 (–22.44, –2.44); p = 0.01; p = 0.40; I2 = 0%] and in neurodegenerative disorder, Wechsler Memory Scale Logical Memory 2 (WMS-LM2) [MD 95% CI = 1.34 (0.83, 1.85); p < 0.00001; p = 0.43; I2 = 0%], showed statistically significant difference, favoring the L-carnosine group over the control group. While in neurodegenerative disorder, Alzheimer ’s Disease Assessment Scale (ADAS) [MD 95% CI = 0.98 (–1.55, –0.42); p = 0.0007; p = 0.86; I2 = 0%] and Back Depression Inventory (BDI) [MD 95% CI = –1.12 (–1.87, –0.37); p = 0.003; p = 0.73; I2 = 0%] showed statistically significant difference, favoring the control group over L-carnosine group. Conclusions: Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease. |
| first_indexed | 2024-04-10T18:47:51Z |
| format | Article |
| id | doaj.art-1e54a20ad41c4bdb9c6a7ff442dc6597 |
| institution | Directory Open Access Journal |
| issn | 2768-6701 |
| language | English |
| last_indexed | 2024-04-10T18:47:51Z |
| publishDate | 2023-01-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj.art-1e54a20ad41c4bdb9c6a7ff442dc65972023-02-01T09:21:18ZengIMR PressFrontiers in Bioscience-Landmark2768-67012023-01-012811810.31083/j.fbl2801018S2768-6701(22)00720-1Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-AnalysisKaoshik Sureshkumar0Mahesh Durairaj1Kaviya Srinivasan2Khang Wen Goh3Krishna Undela4Vijayakumar Thangavel Mahalingam5Chrismawan Ardianto6Long Chiau Ming7Rajanandh Muhasaparur Ganesan8Department of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, 600116 Chennai, Tamil Nadu, IndiaDepartment of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, 600116 Chennai, Tamil Nadu, IndiaDepartment of Pharmacy Practice, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research, 600116 Chennai, Tamil Nadu, IndiaFaculty of Data Science and Information Technology, INTI International University, 71800 Nilai, MalaysiaDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER) Guwahati, Changsari, 781101 Kamrup (R), Assam, IndiaDepartment of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, 603203 Chennai, Tamil Nadu, IndiaDepartment of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, 60115 Surabaya, IndonesiaDepartment of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, 60115 Surabaya, IndonesiaSaveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, 602105 Chennai, Tamil Nadu, IndiaIntroduction: L-carnosine has been found to have multimodal activity. Aim: The aim of this review was to find out the efficacy of L-carnosine in patients with age-related diseases. Methods: Clinical studies evaluated the effect of L-carnosine on cancer, cardiovascular disease, diabetes, and neurodegenerative disorders were searched in electronic bibliographic databases. The protocol has been registered with PROSPERO (CRD42022314033). The revised Cochrane risk of bias tool for randomized trials was used to assess all of the reports for risk of bias. RevMan 5.4 was used to conduct the meta-analysis. Results: Following the screening process, 14 papers were selected for systematic review, with 9 of them being qualified for meta-analysis. Many of the included studies showed that L-carnosine has potential therapeutic activity in age related diseases. Results from the meta-analysis showed that in diabetes mellitus, HbA1c [mean difference (MD) 95% CI = –1.25 (–2.49, –0.022); p = 0.05; p = 0.001; I2 = 85%] and fasting blood sugar (FBS) [MD 95% CI = –12.44 (–22.44, –2.44); p = 0.01; p = 0.40; I2 = 0%] and in neurodegenerative disorder, Wechsler Memory Scale Logical Memory 2 (WMS-LM2) [MD 95% CI = 1.34 (0.83, 1.85); p < 0.00001; p = 0.43; I2 = 0%], showed statistically significant difference, favoring the L-carnosine group over the control group. While in neurodegenerative disorder, Alzheimer ’s Disease Assessment Scale (ADAS) [MD 95% CI = 0.98 (–1.55, –0.42); p = 0.0007; p = 0.86; I2 = 0%] and Back Depression Inventory (BDI) [MD 95% CI = –1.12 (–1.87, –0.37); p = 0.003; p = 0.73; I2 = 0%] showed statistically significant difference, favoring the control group over L-carnosine group. Conclusions: Clinical studies were conducted to manage chemotherapy induced toxicities and there are no clinical studies available for its anti-cancer use, and the current evidence does not support its use in the treatment of cardiovascular disease.https://www.imrpress.com/journal/FBL/28/1/10.31083/j.fbl2801018alzheimer's diseaseamino acidcancerdiabetescardiovascular diseasesneurological diseases2-(3- aminopropanoylamino)-3-(3h-imidazol-4-yl) propanoic acidpolaprezinc |
| spellingShingle | Kaoshik Sureshkumar Mahesh Durairaj Kaviya Srinivasan Khang Wen Goh Krishna Undela Vijayakumar Thangavel Mahalingam Chrismawan Ardianto Long Chiau Ming Rajanandh Muhasaparur Ganesan Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis Frontiers in Bioscience-Landmark alzheimer's disease amino acid cancer diabetes cardiovascular diseases neurological diseases 2-(3- aminopropanoylamino)-3-(3h-imidazol-4-yl) propanoic acid polaprezinc |
| title | Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis |
| title_full | Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis |
| title_fullStr | Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis |
| title_short | Effect of L-Carnosine in Patients with Age-Related Diseases: A Systematic Review and Meta-Analysis |
| title_sort | effect of l carnosine in patients with age related diseases a systematic review and meta analysis |
| topic | alzheimer's disease amino acid cancer diabetes cardiovascular diseases neurological diseases 2-(3- aminopropanoylamino)-3-(3h-imidazol-4-yl) propanoic acid polaprezinc |
| url | https://www.imrpress.com/journal/FBL/28/1/10.31083/j.fbl2801018 |
| work_keys_str_mv | AT kaoshiksureshkumar effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT maheshdurairaj effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT kaviyasrinivasan effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT khangwengoh effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT krishnaundela effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT vijayakumarthangavelmahalingam effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT chrismawanardianto effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT longchiauming effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis AT rajanandhmuhasaparurganesan effectoflcarnosineinpatientswithagerelateddiseasesasystematicreviewandmetaanalysis |